Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 68 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Nephrotic Syndromes Clear all
Recruiting No phase listed Observational

Nephrotic Syndrome Study Network

NCT01209000
View directory record Official record
Conditions
Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions
Kidney Biopsy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Up to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Terminated No phase listed Observational

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

NCT04235621
View directory record Official record
Conditions
Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
Interventions
FSGS/TR-MCD, Diabetic Nephropathy (DN)
Other
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Mesa, Arizona • Glendale, California • Victorville, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 31, 2026, 10:35 PM EDT
Not listed No phase listed Observational

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

NCT03644771
View directory record Official record
Conditions
Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function
Interventions
Acthar
Drug
Lead sponsor
Greater Boston Medical Associates
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional

Atacicept in Multiple Glomerular Diseases

NCT06983028
View directory record Official record
Conditions
pMN, IgAN, Nephrotic Syndrome, MCD, FSGS
Interventions
Atacicept
Drug
Lead sponsor
Vera Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Not applicable Interventional

Vitamin D Supplementation in Glomerular Disease

NCT01835639
View directory record Official record
Conditions
Glomerular Disease
Interventions
Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
Dietary Supplement
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 30 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 31, 2026, 10:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glucocorticoid-induced Osteopenia in Children

NCT00289328
View directory record Official record
Conditions
Crohn's Disease, Nephrotic Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years to 21 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2Phase 3 Interventional

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

NCT00035334
View directory record Official record
Conditions
Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases
Interventions
NC-503 (Anti-amyloidotic (AA) Agent)
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2006 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2 Interventional

Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy

NCT00050713
View directory record Official record
Conditions
Membranous Glomerulonephritis, Lupus Membranous Nepropathy
Interventions
Sirolimus
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

NCT04009668
View directory record Official record
Conditions
FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
adalimumab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
6 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Ann Arbor, Michigan • New York, New York • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases

NCT06664814
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
Interventions
ManNAc
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years to 115 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Terminated Phase 4 Interventional

Steroid Sensitive Nephrotic Syndrome in Children

NCT03878914
View directory record Official record
Conditions
Nephrotic Syndrome in Children
Interventions
Corticosteroids
Drug
Lead sponsor
Wayne State University
Other
Eligibility
1 Year to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

Steroid Treatment for Kidney Disease

NCT00065611
View directory record Official record
Conditions
Nephrosis, Focal Lipoid Glomerulosclerosis
Interventions
Oral dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2011 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients

NCT01601236
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Repository Corticotropin Injection, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Roseville, California • Cooper City, Florida • Miami Springs, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting No phase listed Observational

Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)

NCT06669949
View directory record Official record
Conditions
Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
Interventions
no intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting Phase 2 Interventional

Study of WAL0921 in Patients With Glomerular Kidney Diseases

NCT06466135
View directory record Official record
Conditions
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
Interventions
WAL0921, Placebo
Drug
Lead sponsor
Walden Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 3 Interventional

Prednisolone Trial in Children Younger Than 4 Years

NCT03141970
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
Prednisolone
Drug
Lead sponsor
All India Institute of Medical Sciences
Other
Eligibility
1 Year to 4 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Stanford, California • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Podocyte Retinoids

NCT00098020
View directory record Official record
Conditions
Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
Interventions
Isotretinoin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 2 Interventional Results available

Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)

NCT00001959
View directory record Official record
Conditions
Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
Interventions
Pirfenidone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

NCT05627557
View directory record Official record
Conditions
Childhood Idiopathic Nephrotic Syndrome
Interventions
Obinutuzumab, MMF, Prednisone, Methylprednisolone, Acetaminophen/ Paracetamol, Diphenhydramine Hydrochloride
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Palo Alto, California • Miami, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Terminated No phase listed Observational

Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis

NCT00883636
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Chronic Kidney Disease
Interventions
Cardiovascular Assessment, Renal Assessment, Genetic Evaluation
Other
Lead sponsor
Northwell Health
Other
Eligibility
6 Months to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 31, 2026, 10:35 PM EDT
Completed Phase 4 Interventional

Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes

NCT01021540
View directory record Official record
Conditions
Nephrotic Syndromes
Interventions
Repository corticotrophin
Drug
Lead sponsor
Arizona Kidney Disease and Hypertension Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting No phase listed Observational

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

NCT05650619
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
Interventions
Biospecimen collection, Data collection
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 31, 2026, 10:35 PM EDT
Suspended No phase listed Observational

Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome

NCT03042637
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
Acthar Gel and Tacrolimus
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 31, 2026, 10:35 PM EDT
Recruiting Not applicable Interventional

NEPTUNE Match Study

NCT04571658
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions
Communication
Other
Lead sponsor
University of Michigan
Other
Eligibility
1 Year to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 31, 2026, 10:35 PM EDT